ERBB2 and neoplasm: Our group showed that overexpressing HER-2 in the aggressive MDA-MB-435/LCC6 tumour model9 (LCC6HER-2) increased the tumour’s viability and levels of hypoxia compared to isogenic control tumours transfected with vector alone (LCC6Vector)10.